Patents Assigned to Joint BioSciences Ltd
  • Publication number: 20240131096
    Abstract: The present disclosure provides methods of treating cancer using complementary transgenic oncolytic viruses and genetically engineered CAR T cells. In one embodiment, the oncolytic virus comprises nucleotide sequences encoding CD19, or CD19 and IL-12, and the genetically engineered T cells express a chimeric antigen receptor that recognizes CD19.
    Type: Application
    Filed: October 23, 2023
    Publication date: April 25, 2024
    Applicants: Broaden Bioscience and Technology Corp, Orgenesis, Inc, Joint BioSciences Ltd
    Inventors: BUO CHEN, GUOQING ZHOU, XIANGGUM LI